Rollman Management Invests $5M in Pharmatech AI to Boost AI-Driven Drug Research

Rollman Management, a global investor in emerging technologies, has announced a $5 million investment in Pharmatech AI, a Germany-based company specializing in artificial intelligence (AI) for pharmaceutical research. The funding will support the expansion of a state-of-the-art research center in Germany and the development of the PCH Token, which aims to bridge the pharmaceutical and crypto industries. Pharmatech AI has already garnered attention for its 620,000 m² research facility, marking a significant step forward in AI-driven drug development and sustainable pharmaceutical innovation [1].

Germany has positioned itself as a global leader in medical research, supported by robust infrastructure, a highly skilled workforce, and a favorable regulatory environment. The collaboration between Pharmatech AI and institutions such as the Federal Institute for Drugs and Medical Devices (BfArM) and the EU’s ICH M7 guidelines is playing a key role in advancing AI applications in drug development. The EU’s MiCA regulation also provides clarity for digital assets, enabling investors like Rollman Management to confidently fund innovative projects [1].

Pharmatech AI is addressing regulatory challenges in AI-driven drug research by ensuring compliance with GDPR and Good Manufacturing Practices (GMP). The company’s AI Multi-Drug Interaction Predictor (AI-MDIP), which uses Graph Neural Networks to analyze molecular interactions, requires high-performance computing resources. With the 620,000 m² facility in Germany, including 120,000 m² dedicated to sustainable cannabis production for research purposes, the company is well-positioned to meet the demands of an evolving market [1].

The global drug research market is projected to reach $137.72 billion by 2029, with AI in drug research expected to reach $7.1 billion and the medical cannabis market $41.4 billion by 2030. According to McKinsey, AI has the potential to save $60–110 billion annually by reducing development times by up to 40%. Pharmatech AI’s focus on AI-driven cannabinoid research is addressing a critical gap and attracting interest from major pharmaceutical players [1].

Rollman Management’s investment will allow Pharmatech AI to enhance its computing infrastructure, recruit more AI experts, and expand its research center. The company’s commitment to sustainability is reflected in its research facility, which is powered by 55 MWp of solar energy and designed to be CO2-neutral. The AI-MDIP model, along with an AI-powered cannabis lab that generates thousands of data points per cycle, underscores the company’s innovative approach to pharmaceutical research [1].

Pharmatech AI continues to build strategic partnerships and develop the PCH Token to expand its global pharmaceutical collaborations. Rollman Management’s investment marks a significant milestone in the company’s growth and underscores the increasing role of AI in transforming the pharmaceutical industry [1].

Source: [1] Pharmatech AI Receives $5 Million Investment from Rollman Management to Implement AI in Pharmaceutical Research (https://www.newsbtc.com/press-releases/pharmatech-ai-receives-5-million-investment-from-rollman-management-to-implement-ai-in-pharmaceutical-research/)